TipRanks on MSN

Kelun-Biotech’s ADC-PD-1 combo wins breakthrough therapy status in first-line lung cancer

An announcement from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( ($HK:6990) ) is now available. Sichuan Kelun-Biotech announced ...
abc27

OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting

NEW YORK, Dec. 1, 2025 /PRNewswire/ -- OncoPrecision Corporation ("OncoPrecision"), a translational therapeutics company developing novel antibody-based cancer therapies informed by large-scale ...

Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs

Synaffix B.V. ("Synaffix"), a Lonza company (SWX: LONN) focused on commercializing its clinical-stage platform technology for the ...
Business Wire

2019 Spotlight on Antibody-Drug Conjugates: Pipeline Trends, Strategic Insights, Key Players - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Spotlight on Antibody-Drug Conjugates" report has been added to ResearchAndMarkets.com's offering. The first antibody-drug conjugate (ADC), Mylotarg, reached the market ...
TipRanks on MSN

Kelun-Biotech wins NMPA IND nod for ITGB6-targeted ADC SKB105 and advances oncology collaboration with Crescent

The latest update is out from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( ($HK:6990) ). Sichuan Kelun-Biotech has received ...
BioWorld

First-in-class ADC Foreseen in $1B-plus Ipsen deal

The lively antibody-drug conjugate (ADC) space chalked another collaboration as Taipei, Taiwan-based Foreseen Biotechnology Co. Ltd. scored a global licensing agreement worth as much as $1.03 billion ...
EDN

Renesas’s Intersil Brand 14-Bit, 1-MSPS ADC Delivers Best-in-Class Radiation-Hardened Performance for Satellites, Manned Spacecraft, and Lunar Space Missions

Renesas Electronics Corporation, a premier supplier of advanced semiconductor solutions, today announced the industry’s highest-performance single-chip 14-bit, 1-MSPS successive-approximation-register ...
WGHP

ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in ...

LOTIS-7 trial is on track for complete patient enrollment in 1H 2026; plan to share full data at a medical meeting and submit for publication by end of 2026 Company to host conference call today at ...